Bugs and drugs: The interplay between IBD therapeutics, inflammation and the gut microbiome - implications for colonic carcinogenesis
Best Practice & Research Clinical Gastroenterology · 2026-08 · 83 · 102139
DOI: 10.1016/j.bpg.2026.102139 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Best Practice & Research Clinical Gastroenterology, 2026-08. Verfasst von Kirolos Messiha und 4 weiteren Autor:innen. Beteiligte Einrichtung: Microbiome Research Centre, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia; School of Medicine, The University of N…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Colitis-Associated Neoplasms, Inflammatory Bowel Diseases, Colorectal Neoplasms. Die Arbeit nennt 91 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The McCusker Charitable Foundation.
Abstract (Originalsprache)
With the rising global prevalence of inflammatory bowel disease (IBD) and improved patient longevity, the burden of colitis-associated colorectal cancer (CAC) is increasing. Patients with IBD have a higher risk of developing colorectal cancer (CRC) compared with the general population and are typically diagnosed at a younger age than those with sporadic CRC. This elevated risk is driven by chronic and recurrent inflammatory injury to the intestinal mucosa, which plays a central mechanistic role in carcinogenesis. In contrast to the adenoma-carcinoma sequence observed in sporadic CRC, CAC arises through a distinct inflammation-dysplasia-carcinoma pathway with persistent inflammation initiating and promoting tumorigenesis. Evidence strongly implicates the gut microbiota as being a risk factor in both IBD and CRC. This review synthesises current evidence on the role of the gut microbiota across IBD, CRC and CAC, with a particular focus on the impact of IBD therapeutics on colitis-associated carcinogenesis and the intersection with gut microbiota changes. We identify critical gaps in mechanistic understanding and emphasise the urgent need for mechanism-driven, personalised strategies to enable meaningful clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Microbiome Research Centre, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia; School of Medicine, The University of Notre Dame, Sydney, Australia.
- Microbiome Research Centre, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.
- Microbiome Research Centre, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia. Electronic address: georgina.hold@unsw.edu.au.
Förderung
- The McCusker Charitable Foundation
Zitieren
APA
Messiha, K., Khan, S., Houshyar, Y., Damm, G. K., & Hold, G. L. (2026). Bugs and drugs: The interplay between IBD therapeutics, inflammation and the gut microbiome - implications for colonic carcinogenesis. Best Practice & Research Clinical Gastroenterology, 83, 102139. https://doi.org/10.1016/j.bpg.2026.102139
Vancouver
Messiha K, Khan S, Houshyar Y, Damm GK, Hold GL. Bugs and drugs: The interplay between IBD therapeutics, inflammation and the gut microbiome - implications for colonic carcinogenesis. Best Practice & Research Clinical Gastroenterology. 2026;83:102139. doi:10.1016/j.bpg.2026.102139
BibTeX
@article{Messiha2026,
author = {Messiha, Kirolos and Khan, Shahriar and Houshyar, Yashar and Damm, Gabrielle K and Hold, Georgina L},
title = {Bugs and drugs: The interplay between IBD therapeutics, inflammation and the gut microbiome - implications for colonic carcinogenesis},
journal = {Best Practice & Research Clinical Gastroenterology},
year = {2026},
volume = {83},
pages = {102139},
doi = {10.1016/j.bpg.2026.102139}
}
EUVIMED